Mode
Text Size
Log in / Sign up

Respiratory Tract Infections

Subtypes of Respiratory Tract Infections

Respiratory Viral Infections 5 Lower Respiratory Tract Infection 4 Acute Respiratory Illness 2

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Respiratory Tract Infections

7 trials tracked for Respiratory Tract Infections: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 93 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 3 Other / NA 3
  1. Phase 3 A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy. Completed · 93 cited
  2. Phase 2 A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN Completed
  3. Phase 2 A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS Completed
  4. Phase 2 Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Completed
  5. N/A Home Usability of a Nasal Lavage System in Children Completed
  6. N/A Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR Completed
Show 1 more trials
  1. N/A Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER) Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Respiratory Tract Infections: what the trials found

RSVpreF demonstrated efficacy in reducing medically attended lower respiratory tract illness (MA-LRTI) caused by RSV in infants within various windows following birth: 0.7% vs 1.7% at 90 days 1, 1.1% vs 2.5% at 120 days 1, and 1.5% vs 3.1% at 150 days 1.

An RSV vaccine was evaluated for safety in maternal participants, showing local reactions (ranging from 0.9% to 5.2%) and systemic events (ranging from 0.0% to 2.6%) within 7 days of vaccination, with overall adverse events reported between 22.6% and 30.2% within one month 3.

An RSV vaccine was shown to be highly effective in inducing specific antibody concentrations; 100% of participants achieved anti-Tetanus Toxoid (TTd) levels ≥ 0.1 IU/mL, while 97.4% and 99.3% achieved anti-Diphtheria Toxoid (DTd) levels ≥ 0.1 IU/mL at one month post-vaccination 4. Additionally, geometric mean concentrations for anti-Pertussis antibodies were observed between 36.59 and 257.05 4.

Recent results — preliminary, needs further review

  • Clesrovimab was evaluated in a Phase 2 trial; however, data regarding its safety profile (injection site, systemic, and serious adverse events) are not yet corroborated.
  • Clarithromycin modified release 500 mg showed an 86.9% clinical success rate, though results for fast recovery were variable 5.
  • The use of an automatic nasal irrigator/aspirator device showed a statistically significant number of participants using the device correctly (p=0.0005) 7.

For the clinician treating this condition

  • RSVpreF significantly reduces the incidence of medically attended lower respiratory tract illness in infants within 150 days of birth 1.
  • The RSV vaccine is associated with high rates of antibody production for Tetanus, Diphtheria, and Pertussis 4.
  • Maternal administration of an RSV vaccine shows a manageable safety profile regarding local and systemic reactions 3.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Respiratory Tract Infections

Which group of children had the highest burden of respiratory tract infections after COVID restrictions lifted?

Preschoolers (4–6 years) had the highest burden of respiratory tract infections after COVID restrictions lifted, with a 68.3% pathogen detection rate.

Full answer →
Can parechovirus A cause pharyngitis and tonsillitis in hospitalized children?

Yes, parechovirus A can cause pharyngitis and tonsillitis in hospitalized children, especially when detected alone without other viruses.

Full answer →
Are frequent snacks linked to more frequent respiratory tract infections in preschoolers?

Frequent snacks are linked to a higher risk of recurrent respiratory tract infections in preschoolers, according to a meta-analysis of global studies.

Full answer →
Can passive smoking increase the risk of recurrent respiratory tract infections in young children?

Yes, passive smoking is a significant risk factor that increases the likelihood of recurrent respiratory tract infections in young children.

Full answer →
Does having asthma make a preschooler more likely to get a respiratory tract infection?

Yes, asthma significantly increases a preschooler's risk of recurrent respiratory tract infections, with meta-analysis showing about 3 times higher odds.

Full answer →
See all 5 questions about Respiratory Tract Infections →

All Respiratory Tract Infections Articles